What is the Avalo Therapeutics Inc. stock price forecast?

Avalo Therapeutics Inc. is currently trading at $21.81. View real-time AI analysis on Alpha Lenz.

What is Avalo Therapeutics Inc. insider trading activity?

View the latest insider trading data for Avalo Therapeutics Inc. on Alpha Lenz.

What is Avalo Therapeutics Inc.'s P/E ratio?

Avalo Therapeutics Inc.'s P/E ratio is -2.7.

Avalo Therapeutics Inc.

NASDAQ · AVTX

$21.81+5.55(+34.13%)

Ask about Avalo Therapeutics Inc.'s future dividend policy...

Alpha Chat Insight

“Avalo Therapeutics Inc. trades at a P/E of -2.7 (undervalued) with modest ROE of -50.1%.”

Ask for details →

Company Overview

Avalo Therapeutics Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapies for the treatment of rare and immune-mediated diseases. The primary aim of the company is to address unmet medical needs with a focus on achieving significant clinical results for patients. Avalo's pipeline includes a variety of drug candidates that target specific pathways pertinent to its therapeutic areas. The company's research and development efforts emphasize innovation in both drug molecules and treatment methodologies, looking to provide effective solutions in niches often overlooked by larger pharmaceutical entities. Operating predominantly in the biotechnology and healthcare sectors, Avalo Therapeutics Inc. plays a crucial role in advancing medical research and offering potential new treatment options for conditions that have limited solutions available in the market today.

CEODr. Garry A. Neil M.D.

Websitehttps://www.avalotx.com

SectorHealthcare

IndustryBiotechnology

Employees23

Company Statistics

FY 2024

Profile

$96.53MMarket Cap

$441.00KRevenue

0.00Shares Out

23Employees

Margins

182.99%Gross

-22341.95%EBITDA

-15535.60%Operating

-7939.91%Pre-Tax

-7965.76%Net

Valuation

-2.75P/E

0.73P/B

218.90EV/Sales

0.38EV/EBITDA

-1.97P/FCF

Growth (CAGR)

-56.61%Rev 3Yr

-42.05%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-40.91%ROA

-50.06%ROE

-79.79%ROIC

Financial Health

$134.55MCash & Cash Equivalents

$-116.85MNet Debt

13.31%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Avalo Therapeutics Inc. trades at a P/E of -2.7 (undervalued) with modest ROE of -50.1%.”

Ask for details →

Frequently Asked Questions

Avalo Therapeutics Inc. (ticker: AVTX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 23 employees. Market cap is $97M.

The current price is $21.81 with a P/E ratio of -2.75x and P/B of 0.73x.

ROE is -50.06% and operating margin is -15535.60%. Annual revenue is $441,000.